ライフサイエンスコーパス: ribavirin

1 f elbasvir and grazoprevir, with and without ribavirin.

2 f elbasvir and grazoprevir, with and without ribavirin.

3 nfection who were treated with a PEG-IFN and ribavirin.

4 nts treated for short durations with SOF and ribavirin.

5 12), and safety of ledipasvir/sofosbuvir +/- ribavirin.

6 ot transversion mutations in the presence of ribavirin.

7 lls that were left untreated or treated with ribavirin.

8 sofosbuvir and velpatasvir with and without ribavirin.

9 th Pegylated interferon-alpha (Peg-IFN) plus ribavirin.

10 ombitasvir, paritaprevir, and ritonavir plus ribavirin.

11 ere given sofosbuvir and velpatasvir without ribavirin.

12 hieved SVR12 after 8 weeks of treatment with ribavirin.

13 to 16 weeks); 169 of these patients received ribavirin.

14 itonavir orally once daily plus weight-based ribavirin.

15 sa fever, both alone and in combination with ribavirin.

16 tent as the clinically used antiviral agent, ribavirin.

17 vir, and 96% with 100 mg of velpatasvir plus ribavirin.

18 hose with standard treatment with sofosbuvir-ribavirin.

19 tional nucleoside analogs, 5-azacytidine and ribavirin.

20 mg of velpatasvir once daily with or without ribavirin.

21 ledipasvir and sofosbuvir, once daily, plus ribavirin.

22 ek regimen (33 with ribavirin and 32 with no ribavirin.

23 00%) receiving ledipasvir and sofosbuvir and ribavirin.

24 of response to treatment with sofosbuvir and ribavirin.

25 extended treatment duration and addition of ribavirin.

26 , ruzasvir, and uprifosbuvir with or without ribavirin.

27 nt-experienced with pegylated interferon and ribavirin.

28 that do not require IFN and may not require ribavirin.

29 patasvir, 97% with 25 mg of velpatasvir plus ribavirin, 100% with 100 mg of velpatasvir, and 96% with

30 0 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day; Panel 2-Arm 2 (n = 9; GT1b):

31 s) or peginterferon alfa 2b (1.5 mcg/kg/wk), ribavirin (1000-1200 mg/day), and sofosbuvir (400 mg/day

32 r treatment-naive patients; (2) sofosbuvir + ribavirin, 12 weeks for patients with genotype 2, 24 wee

33 cirrhosis; (5) sofosbuvir + peginterferon + ribavirin, 12 weeks for patients with or without cirrhos

34 r patients with cirrhosis; (4) Viekira Pak + ribavirin, 12 weeks for patients without cirrhosis, 24 w

35 and 311 receiving ledipasvir-sofosbuvir plus ribavirin (212 for 12 weeks and 81 for 24 weeks, 18 for

36 ment strategies include: (1) peginterferon + ribavirin, 24 weeks for treatment-naive patients; (2) so

37 tonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions).

38 Through this pathway, the antiviral compound ribavirin 5'-monophosphate is significantly incorporated

39 asvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin (6%).

40 seltamivir (75 mg), amantadine (100 mg), and ribavirin (600 mg) combination therapy or oseltamivir mo

41 00 mg) once daily (combination tablet), plus ribavirin (600-1200 mg daily).

42 ype 2 infection (treated with sofosbuvir and ribavirin), 74.8% (95% CI, 72.2%-77.3%) of those with ge

43 treated with sofosbuvir (SOF)/ledipasvir +/- ribavirin (85%) followed by SOF + daclatasvir +/- ribavi

44 in patients given ledipasvir/sofosbuvir plus ribavirin, 87.0% in patients given sofosbuvir and pegyla

45 neteen participants commenced sofosbuvir and ribavirin (89% male, 74% with human immunodeficiency vir

46 irin (85%) followed by SOF + daclatasvir +/- ribavirin (9%) and ombitasvir/paritaprevir/ritonavir + d

47 of patients received LDV/SOF with or without ribavirin (91%) and were treated for 12 weeks.

48 Treatment options include administration of ribavirin, a purine analog, although the mechanism of it

49 atasvir (400 mg/100 mg) plus weight-adjusted ribavirin administered for 24 weeks in patients who did

50 ose combination of ledipasvir/sofosbuvir +/- ribavirin administered for 8, 12, or 24 weeks in patient

51 Ribavirin administration blocked the growth of primary b

52 The mechanism of action of ribavirin against HRSV is not well understood, although

53 60 patients to the 12-week regimen (31 with ribavirin and 29 with no ribavirin) and 63 to the 18-wee

54 irin) and 63 to the 18-week regimen (32 with ribavirin and 31 with no ribavirin); in cohort 2, we ran

55 irin) and 65 to the 18-week regimen (33 with ribavirin and 32 with no ribavirin.

56 65 patients to the 12-week regimen (32 with ribavirin and 33 with no ribavirin) and 65 to the 18-wee

57 3-Arm 1 and Panel 3-Arm 2, 6/7 (86%) GT1a + ribavirin and 4/8 (50%) GT1b without ribavirin patients,

58 esistant to the mutagenic nucleoside analogs ribavirin and 5-fluorouracil than the WT virus, whereas

59 st human cases treated with a combination of ribavirin and favipiravir.

60 Treatment was targeted against hepatitis C (ribavirin and interferon) in addition to immunosuppressi

61 tion of simeprevir + TMC647055/ritonavir +/- ribavirin and of the 3-DAA combination of simeprevir + T

62 For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $

63 HCV infection is based on interferon-alpha, ribavirin and the new direct-acting antivirals (DAAs), s

64 ere treated for 24 weeks with sofosbuvir and ribavirin and underwent sampling longitudinally.

65 ek regimen (31 with ribavirin and 29 with no ribavirin) and 63 to the 18-week regimen (32 with ribavi

66 ek regimen (32 with ribavirin and 33 with no ribavirin) and 65 to the 18-week regimen (33 with ribavi

67 HCV treatment (interferon with or without ribavirin) and SVR (RNA test negative at least 12 weeks

68 and 70.6% of patients given sofosbuvir plus ribavirin), and 89.6% (95% CI 82.8%-93.9%) of those with

69 Sixty-one patients received sofosbuvir and ribavirin, and 46 received transplanted livers.

70 ven sofosbuvir and pegylated-interferon plus ribavirin, and 70.6% of patients given sofosbuvir plus r

71 by sofosbuvir plus pegylated interferon and ribavirin, and all-oral therapies where available, but c

72 fluence the outcome of retreatment with SOF, ribavirin, and pegylated interferon.

73 d no impact on retreatment outcome with SOF, ribavirin, and pegylated interferon.

74 We compared a regimen of peginterferon, ribavirin, and sofosbuvir with a regimen of simeprevir a

75 reated with combination pegylated IFN-alpha, ribavirin, and telaprevir/boceprevir.

76 4-week no ribavirin arm and the 16-week plus ribavirin arm (lost to follow-up, n = 1), respectively.

77 enotype (GT)1 participants in the 24-week no ribavirin arm and the 16-week plus ribavirin arm (lost t

78 24 weeks for genotype 3; (3) peginterferon + ribavirin as initial treatment, 24 weeks for patients wi

79 ct-acting antiviral regimens with or without ribavirin as treatment of chronic hepatitis C virus in s

80 ir at 400 mg once daily (NS5B inhibitor) and ribavirin at 600 mg/day for 12 weeks with a 24-week foll

81 d during retreatment, 1 patient discontinued ribavirin because of pruritus.

82 ed up to 48 weeks of sofosbuvir (400 mg) and ribavirin before liver transplantation.

83 perspective, HCV therapy using LDV/SOF with ribavirin before LT is the most cost-effective strategy

84 ombitasvir, paritaprevir, and ritonavir plus ribavirin beyond 12 weeks seems to have no additional be

85 Ribavirin can be used in children who are extremely ill

86 An early response to ribavirin can be used to define the optimal duration of

87 treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causin

88 the virus more susceptible to inhibition by ribavirin, coincident with the accumulation of ribavirin

89 Sofosbuvir and ribavirin combination therapy for 24 weeks is an effecti

90 s who achieved SVR vs those who relapsed was ribavirin concentration at the end of treatment.

91 50/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response

92 verse events occurred more frequently in the ribavirin-containing arms of the studies.

93 no virological failures were recorded in the ribavirin-containing regimen.

94 eek regimen of elbasvir and grazoprevir plus ribavirin could increase efficacy in patients with HCV g

95 rm treatment with interferon (IFN) alfa plus ribavirin decreases the proviral human immunodeficiency

96 of elbasvir and grazoprevir, with or without ribavirin, demonstrated high rates of sustained virologi

97 12 or 24 weeks treatment of peginterferon + ribavirin dependent on HCV RNA level at week 12; (2) Har

98 The addition of ribavirin did not appear to increase SVR12 but was assoc

99 We found that ribavirin did not cause a detectable change in the relat

100 Ribavirin did not influence SVR rates and was more often

101 fe in LT, KT, and DLK transplant recipients; ribavirin did not influence SVR, and graft rejection was

102 regimens (pegylated interferon alpha 2b and ribavirin different dosages, and long-term treatment wit

103 0 mg ritonavir once daily, with weight-based ribavirin dosed twice daily for either 12 weeks or 16 we

104 uvir (400 mg) or ledipasvir, sofosbuvir, and ribavirin (dosed according to the Japanese Copegus produ

105 grazoprevir, ruzasvir, and uprifosbuvir plus ribavirin due to serious adverse events of vomiting and

106 tients who received pegylated interferon and ribavirin during 2004-2013 were followed until December

107 In addition, we tested ribavirin efficacy in vivo, alone and in combination wit

108 inical responses to the m(7)G-cap competitor ribavirin, eIF4E is mainly cytoplasmic.

109 cohort treated with pegylated interferon and ribavirin experienced only 10% SVR12, with 100% experien

110 857 (100 mg) once daily for 6-12 weeks, plus ribavirin for 1 treatment group consisting of treatment-

111 ho were treated with EBR/GZR with or without ribavirin for 12 or 16 weeks.

112 tide analogue NS5B polymerase inhibitor) +/- ribavirin for 12 or 24 weeks in HCV genotype (GT)1-infec

113 d patients receiving simeprevir+sofosbuvir+/-ribavirin for 12 or 24 weeks.

114 Ombitasvir, paritaprevir, and ritonavir plus ribavirin for 12 weeks achieved SVR12 in a high proporti

115 with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir-velpatasvir f

116 fosbuvir plus ledipasvir, or sofosbuvir plus ribavirin for 12 weeks are all suitable.

117 for 24 weeks or sofosbuvir, daclatasvir, and ribavirin for 12 weeks are the optimal oral therapies, p

118 Sofosbuvir-ribavirin for 12 weeks for the treatment of acute HCV ge

119 hereas sofosbuvir, pegylated interferon, and ribavirin for 12 weeks is an alternative regimen.

120 Grazoprevir and elbasvir with ribavirin for 12 weeks maintained HCV suppression for at

121 ombination of sofosbuvir, peginterferon, and ribavirin for 12 weeks produces high rates of SVR.

122 ligible for retreatment with EBR/GZR+SOF and ribavirin for 12 weeks.

123 en ledipasvir/sofosbuvir in combination with ribavirin for 12 weeks.

124 onavir (100 mg) with or without weight-based ribavirin for 12 weeks.

125 osbuvir (90 mg and 400 mg) plus weight-based ribavirin for 12 weeks.

126 Sofosbuvir and ribavirin for 12-24 weeks is safe and well tolerated in

127 e 2/3, follow-up treatment with sofosbuvir + ribavirin for 12/16 weeks are performed on non-responder

128 rifosbuvir 450 mg alone for 24 weeks or with ribavirin for 16 weeks.

129 cruited before treatment with interferon and ribavirin for 24 to 48 weeks, according to HCV genotype.

130 acy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus

131 d therapies with sofosbuvir-velpatasvir plus ribavirin for 24 weeks was well tolerated and effective,

132 herapy (21 patients received sofosbuvir plus ribavirin for 24 weeks, 4 patients received sofosbuvir p

133 ronic hepatitis E virus infection were given ribavirin for 3 months.

134 was to assess the efficacy of sofosbuvir and ribavirin for 6 weeks in individuals with recent HCV inf

135 ination of sofosbuvir and ledipasvir without ribavirin for 8 or 12 weeks.

136 d velpatasvir, 25 or 100 mg, with or without ribavirin for 8 weeks.

137 and efficacy of 12 weeks of sofosbuvir plus ribavirin for the treatment of acute HCV infection in pa

138 ir may be considered as an add-on therapy to ribavirin for the treatment of chronic hepatitis E in im

139 eks of ledipasvir/sofosbuvir with or without ribavirin for the treatment of treatment-naive and treat

140 evir, and ritonavir, plus dasabuvir, without ribavirin, for 12 weeks.

141 ruzasvir, and uprifosbuvir, with or without ribavirin, for 16 or 24 weeks was safe and highly effect

142 evir, and ritonavir, plus dasabuvir, without ribavirin, for 8 weeks was efficacious and well tolerate

143 is study assessed the efficacy and safety of ribavirin-free coformulated glecaprevir/pibrentasvir (G/

144 In the ribavirin-free group, two (5%) of 42 treatment-naive pat

145 e safety and efficacy of the interferon- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney t

146 e safety and efficacy of the interferon- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney t

147 nd tolerance of an all-oral, interferon- and ribavirin-free regimen of sofosbuvir plus daclatasvir in

148 S3/4A protease inhibitor)-an interferon- and ribavirin-free regimen-in difficult-to-treat patients, i

149 Furthermore, the interferon- and ribavirin-free SOF/VEL regimen resulted in a rapid impro

150 Patients receiving ribavirin-free SOF/VEL reported significantly better PRO

151 The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens require

152 The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral re

153 e 2 disease) treated with peg-interferon and ribavirin from June 2001 through December 2009 at the Un

154 who were treated with DAAs, with or without ribavirin, from 2014 through 2016 (129 patients achieved

155 11,327), or PrOD (n = 3174), with or without ribavirin, from January 1, 2014 through June 20, 2015 in

156 of 94% (95% CI, 88 to 97) in the sofosbuvir-ribavirin group (P=0.02).

157 general population); regimens that included ribavirin had more mild or moderate adverse events than

158 The addition of ribavirin had no detectable effects on SVR.

159 f chronic hepatitis C, subjects who received ribavirin had reduced lymphocyte levels (median decline

160 Sofosbuvir/ribavirin had the lowest risk to cause a potentially sig

161 Pegylated interferon plus ribavirin has been replaced by sofosbuvir plus pegylated

162 Ribavirin has been used, but case studies show no impact

163 Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Ess

164 In the absence of ribavirin, HRSV-specific transcripts accounted for up to

165 ntrols treated with pegylated interferon and ribavirin in a single health care network.

166 d the all-oral combination of sofosbuvir and ribavirin in adolescents aged 12-17 with hepatitis C vir

167 of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patient

168 evir, and ritonavir, plus dasabuvir, without ribavirin in patients infected with HCV genotype 1b with

169 d efficacy of ledipasvir and sofosbuvir plus ribavirin in patients with genotype 3 HCV infection.

170 and efficacy of ledipasvir, sofosbuvir, and ribavirin in patients with HCV genotype 1 or 4 and advan

171 ase inhibitor; co-dosed with ritonavir) plus ribavirin in patients with HCV genotype 4 infection and

172 rotease inhibitor dosed with ritonavir, plus ribavirin in treatment of chronic HCV infection in Egypt

173 nd the NS5A inhibitor elbasvir together with ribavirin in treatment-experienced patients with chronic

174 ergistic interaction between favipiravir and ribavirin in vitro and an increased survival rate and ex

175 administered with dasabuvir (with or without ribavirin) in a prospective study of patients with stage

176 ek regimen (32 with ribavirin and 31 with no ribavirin); in cohort 2, we randomly assigned 65 patient

177 sis who had failed pegylated interferon plus ribavirin, in 25 of 28 (89%) patients with HCV genotype

178 ruzasvir, and uprifosbuvir, with or without ribavirin, in participants who had failed an NS5A inhibi

179 f ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 infection.

180 bavirin, coincident with the accumulation of ribavirin-induced G-->A and C-->U mutations in viral RNA

181 Our work showed that ribavirin inhibits glioma cell growth and migration, and

182 As previously reported, ribavirin is an effective antiviral drug against many RN

183 However, ribavirin is associated with hemolytic events and is poo

184 gylated interferon alpha 2a or alpha 2b plus ribavirin is more cost-effective than a palliative care

185 of elbasvir and grazoprevir, with or without ribavirin is safe and effective for patients with HCV ge

186 Long-term treatment with ribavirin is safe in liver transplant recipients, withou

187 Ribavirin is the only antiviral treatment option for non

188 Ribavirin is used as an experimental therapy with other

189 ess of ledipasvir/sofosbuvir with or without ribavirin (LDV/SOF +/- RBV) and ombitasvir/ paritaprevir

190 DDIs between all these drugs and sofosbuvir/ribavirin, ledipasvir/sofosbuvir, sofosbuvir/daclatasvir

191 ved sofosbuvir 400 mg daily and weight-based ribavirin (<75 kg, 1,000 mg/day; >/=75 kg, 1,200 mg/day)

192 Ribavirin monotherapy and a minimization of immunosuppre

193 ferent dosages, and long-term treatment with ribavirin monotherapy still ongoing) but without achievi

194 etectable in the serum and stools throughout ribavirin monotherapy.

195 ith HCV genotype 1a infections also received ribavirin (n = 13), whereas those with genotype 1b infec

196 tients given sofosbuvir and velpatasvir plus ribavirin (n=87), PRO scores decreased within 4 weeks of

197 Here, we report the effect of ribavirin on proliferation, cell cycle, cell death and m

198 mg of velpatasvir once daily with or without ribavirin or 100 mg of velpatasvir once daily with or wi

199 ction of immunosuppression or treatment with ribavirin or pegylated interferon-alpha can result in vi

200 prior interferon or pegylated interferon +/- ribavirin or sofosbuvir plus ribavirin +/- pegylated int

201 eron or pegylated interferon with or without ribavirin, or sofosbuvir plus ribavirin with or without

202 g + TMC647055 450 mg/ritonavir 30 mg without ribavirin; Panel 3: simeprevir 75 mg + TMC647055 600 mg/

203 GT1a; n = 7) or without (Arm 2: GT1b; n = 8) ribavirin; Panel 4: simeprevir 75 mg + TMC647055 450 mg/

204 nel 2-Arm 1, 5/10 and 6/12 (50%) GT1a/GT1b + ribavirin patients achieved SVR12, versus 3/9 (33%) GT1b

205 chieved SVR12, versus 3/9 (33%) GT1b without ribavirin patients in Panel 2-Arm 2.

206 GT1a + ribavirin and 4/8 (50%) GT1b without ribavirin patients, respectively, achieved SVR12.

207 ntrols treated with pegylated interferon and ribavirin; patients with glomerulonephritis experienced

208 interferon +/- ribavirin or sofosbuvir plus ribavirin +/- pegylated interferon therapy) patients wit

209 with >/= 4 weeks of pegylated interferon and ribavirin plus either boceprevir, telaprevir, or simepre

210 d to treatment with pegylated interferon and ribavirin (PR), and a protease inhibitor for HCV genotyp

211 Indeed, m(7)G cap analogs or ribavirin prevents nuclear entry of eIF4E, which mirrors

212 Ledipasvir-sofosbuvir and ribavirin provided high rates of SVR12 for patients with

213 We evaluated the antiviral activities of ribavirin (RBV) and interferon (IFN) alfa as monotherapy

214 s (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks.

215 ng simeprevir and sofosbuvir with or without ribavirin (RBV) for 12 weeks resulted in high sustained

216 vir-velpatasvir-voxilaprevir with or without ribavirin (RBV) for 12 weeks.

217 llowing strategies: peg-interferon (PEG-IFN)/ribavirin (RBV) for 48 weeks, PEG-IFN/RBV plus boceprevi

218 fety of ABT-493 plus ABT-530 with or without ribavirin (RBV) in GT1- or GT3-infected patients with co

219 f glecaprevir (GLE) + pibrentasvir (PIB) +/- ribavirin (RBV) in HCV genotype 1-infected patients with

220 responses (SVR) of SIM+SOF with and without ribavirin (RBV) in patients with Child-Pugh (CP)-B/C ver

221 tained virologic response (SVR) of LDV/SOF+/-ribavirin (RBV) in routine medical practice.

222 LLY-3+ study (N = 50) evaluated DCV-SOF with ribavirin (RBV) in treatment-naive (n = 13) or treatment

223 tonavir with dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (RBV) is approved for hepatitis C virus (HCV)

224 r (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological re

225 ts who received pegylated IFN (PEG-IFN) plus ribavirin (RBV) therapy.

226 Sofosbuvir (SOF) + daclatasvir +/- ribavirin (RBV) was used in 123 patients, SOF + RBV in 3

227 This shift was blocked by ribavirin (RBV), an antiviral drug that reduces relapse

228 imeprevir (SMV)/SOF, 94% (16/17) for SMV/SOF/ribavirin (RBV), and 52% (16/31) for SOF/RBV.

229 d patients treated with interferon (IFN) and ribavirin (RBV), between 2000 and 2008.

230 on SOF-based regimens (SOF + simeprevir +/- ribavirin (RBV), n = 53; SOF + pegylated interferon + RB

231 DCV) plus pegylated interferon (Peg-IFN) and ribavirin (RBV), with (n = 3) or without (n = 13) asunap

232 ilable for 197 patients treated with SOF and ribavirin (RBV), with or without peginterferon, includin

233 nts taking 8, 12, or 24 weeks of LDV/SOF +/- ribavirin (RBV).

234 nce daily for 12 to 24 weeks with or without ribavirin (RBV).

235 ter liver transplantation include the use of ribavirin (RBV).

236 /ritonavir + dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (RBV).

237 gylated interferon-alpha (Peg-IFN-alpha) and ribavirin regimens.

238 y mild, with the exception of 1 patient with ribavirin-related anemia requiring blood transfusion.

239 the basis of these results, we propose that ribavirin represents a new therapeutic option for gliobl

240 and only four patients (4%) of 91 receiving ribavirin required dose modification for haemoglobin les

241 suggesting that recombination contributes to ribavirin resistance.

242 on and that RNA recombination contributes to ribavirin resistance.

243 and W237L(LF) mutant viruses exhibited lower ribavirin resistance.

244 Ribavirin-resistant mutants reemerged by escaping lethal

245 In the present study, these ribavirin-resistant mutants were evaluated in terms of t

246 sequently, in the present study, both of the ribavirin-resistant mutants were evaluated in terms of t

247 In a previous study, ribavirin-resistant porcine reproductive and respiratory

248 In a previous study, two ribavirin-resistant PRRSV mutants (RVRp13 and RVRp22) we

249 A similar regimen with ribavirin resulted in a temporary decrease in PROs, whic

250 Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect.

251 The presented data reveal that ribavirin significantly increases the frequency of HRSV-

252 6, sofosbuvir plus pegylated interferon and ribavirin, sofosbuvir plus ledipasvir, or sofosbuvir plu

253 ent with interferon or pegylated interferon, ribavirin, sofosbuvir, or a combination of these medicat

254 ) for G1/4 and treatment with Sofosbuvir and ribavirin (SR) for G2/3 increased QALYs by 555 226, redu

255 virus more susceptible to the antiviral drug ribavirin, suggesting that recombination contributes to

256 Among patients also receiving ribavirin, SVR12 was achieved by 97% of the patients rec

257 genotype 1, we compare: (1) peginterferon + ribavirin + telaprevir for 12 weeks, followed by 12 or 2

258 al therapy is limited to an off-label use of ribavirin that is only partially effective.

259 herapy being limited to the off-label use of ribavirin that is only partially effective.

260 Ribavirin, the only clinically approved drug known to ta

261 Ribavirin therapy was interrupted in 9 patients due to a

262 of chronically infected patients undergoing ribavirin therapy.

263 thout concomitant pegylated interferon-alpha/ribavirin therapy.

264 e enrolled as a part of an efficacy trial of ribavirin therapy.

265 Background: Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infec

266 Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infec

267 on SVR reported for pegylated interferon and ribavirin) to achieve superiority.

268 ble for >100 days after HEV RNA clearance in ribavirin-treated patients with chronic HEV.

269 tment responses to pegylated interferon plus ribavirin treatment (PegIFN/RBV) have not been fully ill

270 However, we found that ribavirin treatment did indeed cause an increase in the

271 atified by previous pegylated interferon and ribavirin treatment experience using a web-based interac

272 We also demonstrate that ribavirin treatment in combination with temozolomide or

273 Finally and most importantly, ribavirin treatment in vivo significantly enhances chemo

274 Ribavirin treatment resulted in a >90% reduction in abun

275 e and interferon or pegylated interferon and ribavirin treatment-experienced patients with HCV genoty

276 11 to 50 of P and formally demonstrate that ribavirin triphosphate (RTP) inhibits the RdRP.

277 ofosbuvir 400 mg once daily and weight-based ribavirin twice daily for 12 (genotype 2) or 24 (genotyp

278 once daily coadministered with weight-based ribavirin twice daily for 12 weeks in genotype 1-infecte

279 svir/sofosbuvir) once daily, with or without ribavirin twice daily.

280 Treatment with interferon and ribavirin upregulated beta-defensin-1, but not other bet

281 ics, use of antidepressants, use of opioids, ribavirin use, the presence of ascites, encephalopathy,

282 combination of oseltamivir, amantadine, and ribavirin versus oseltamivir monotherapy with matching p

283 R12 for the 16-week regimen with and without ribavirin was achieved in 26 (100% [95% CI 87-100]) of 2

284 R12 for the 12-week regimen with and without ribavirin was achieved in 28 (97% [95% CI 82-100]) of 29

285 ruzasvir, and uprifosbuvir with and without ribavirin was achieved in 39 (93% [95% CI 81-99]) of 42

286 R12 for the 12-week regimen with and without ribavirin was achieved in 87 (99% [95% CI 94-100]) of 88

287 The addition of ribavirin was associated with increased SVR rates for ce

288 gylated interferon alpha 2a or alpha 2b plus ribavirin was dominant or cost-saving in Thailand compar

289 Sofosbuvir and ribavirin was safe and highly effective in adolescents w

290 Six weeks of sofosbuvir and ribavirin was safe and well tolerated, but efficacy was

291 combination of daclatasvir, sofosbuvir, and ribavirin was safe and well tolerated.

292 imeprevir or sofosbuvir/pegylated interferon/ribavirin, was included for comparison.

293 A 5'-diphosphate form of antiviral ribavirin weakly inhibited the GpppA formation but did n

294 weeks, sofosbuvir and velpatasvir plus oral ribavirin (weight-based 1000 mg or 1200 mg) for 12 weeks

295 nterruptions of study medications, including ribavirin, were noted, and only four patients (4%) of 91

296 tay of HBV and HCV therapy over decades, and ribavirin, which has also been included in interferon-fr

297 egylated interferon alpha 2a or alpha 2b and ribavirin with a usual palliative care for genotype 1 an

298 ith or without ribavirin, or sofosbuvir plus ribavirin with or without pegylated interferon.

299 ailed prior treatment with peginterferon and ribavirin without (46%) or with telaprevir or boceprevir

300 tional therapy with pegylated interferon and ribavirin yields approximately 40% sustained virologic r